Bio

Jason’s practice focuses on licensing, corporate partnerships, and other intellectual property, technology-, and product-related transactions, primarily for clients in the biotechnology, pharmaceutical, and medical device industries. He is the leader of the firm’s Licensing and Technology Transactions practice group.

Jason received his B.S. in Biology from Duke University and his M.S. in Biology from the University of California, San Diego. He earned his J.D. from the University of Virginia School of Law, where he was an editor of the Virginia Law Review and elected member of the Order of the Coif.

Prior to attending law school, Jason worked in the Office of Technology Development at The Scripps Research Institute in La Jolla, California, where he managed the Institute’s relationships with major pharmaceutical companies and negotiated licenses and other agreements with emerging ventures.

  • Listed among The Best Lawyers in America: Biotechnology and Life Sciences Practice (2009-2021)
  • Best Lawyers® Raleigh 2021 “Lawyer of the Year” Biotechnology and Life Sciences Practice
  • Listed among Business North Carolina Magazine Legal Elite: Intellectual Property (2016)
  • Listed among “IAM Patent 1000–The World’s Leading Patent Practitioners” as “Recommended” for Licensing (2012, 2013) and for Transactions (2014-2019) by Intellectual Asset Management
  • Listed among “The World’s Leading Patent & Technology Licensing Lawyers” by IAM Licensing 250 (2011)
  • Listed among LMG Life Sciences: “Life Sciences Stars” (2012, 2013)
  • Listed among North Carolina Super Lawyers “Rising Stars” Business/Corporate (2010, 2011)
  • Licensing Executives Society (Co-Chair of RTP Chapter 2010-2013)
  • Association of University Technology Managers
  • American Bar Association
  • North Carolina Bar Association
  • Wake County Bar Association
  • Council for Entrepreneurial Development
  • Represented global pharmaceutical company in collaboration involving novel platform technology for the design/generation of novel antibodies for cancer indications
  • Represented venture-backed pharmaceutical company in strategic partnership with international biopharma company for the development and commercialization of lead product in Europe
  • Represented agbiotech company in strategic partnership with large international seed company involving platform-based discovery of insect resistance traits with unique modes of action and development/commercialization of corresponding transgenic crops
  • Represented global pharmaceutical company in transaction involving novel platform technology for the identification of antigen targets for use in cancer vaccines and CAR-T
  • Represented CRISPR-based early-stage venture in collaboration with publicly-traded biopharma to discover/characterize novel targets and/or therapies for certain cancers
  • Represented publicly-traded pharmaceutical company in co-development and license agreements with global pharmaceutical company for clinical-stage GI and antibacterial therapies
  • Represented publicly-traded pharmaceutical company in partnership for the development/commercialization of clinical-stage novel antibiotic in Japan
  • Represented publicly-traded pharmaceutical company in multiple transactions involving novel drug delivery technology in pain and opioid dependence indications
  • Represented medical device incubator in multiple licenses of its technologies/products to commercial partners
  • Represented numerous companies in the licensing of early-stage therapeutic, diagnostic, medical device, and platform technologies from universities
  • “Licensing 201: Advanced Concepts,” 2004 Eastern Regional Meeting, Association of University Technology Managers, Charleston, SC
  • “Licensing University-Based Technology,” The Art of Advising Emerging Growth Companies, University of North Carolina School of Law, November 2004
  • “Protecting and Profiting from your Government-Funded IP,” SBIR/ R&D Conference, RTP, NC, November 2005
  • “Strategic Partnerships: Leveraging the Resources of Others to Advance Your Technology and Business,” North Carolina State University Technology Incubator, November 2005
  • “Exploiting Intellectual Property: Licensing and Strategic Partnerships,” Duke Start-Up Challenge, February 2006
  • “Patents and Licensing University Technologies,” Kauffman Foundation's eVenturing.org, August 2006
  • “Exploiting Intellectual Property: Licensing and Strategic Partnerships,” SBIR/STTP Seminar: Funding for Innovation in North Carolina, Raleigh, NC, October 2007
  • “Licensing Pitfalls: Looking Past Rights and Royalties When Acquiring Technology,” TechJournal South, April 2008
  • “Introduction to Joint Ventures,” North Carolina Bar Association's Business Law and Corporate Counsel Sections Joint Annual Meeting, Pinehurst, NC, February 2009
  • “Navigating Rough Waters in Pharmaceutical and Biotechnology Partnerships,” North Carolina Bar Association Intellectual Property Law Section Annual Meeting, Greensboro, NC, April 2010
  • “Licensing University Technology,” NC BioStart Commercialization Webinar Series, April 2010
  • “Negotiating and Managing Strategic Alliances,” CED Biotech Conference 2011, Raleigh, NC, February 2011
  • “What Happens After Closing: Lessons Learned from Managing Bio-Pharmaceutical Alliances,” Joint LES/ASAP RTP Chapters Seminar, March 2011
  • “The University and Entrepreneurs – Research and Technology Collaboration,” Continuing Legal Education Program: Representing Entrepreneurs and Start-Up Businesses, NC State Lawyers Alumni Annual Meeting, Raleigh, NC, November 2014
  • Wyrick Robbins Intellectual Property Attorneys Featured on eVenturing.org